Gestational Diabetes Market Expansion Continues, with Forecast Valuation of $12.78 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Gestational Diabetes Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Strong expansion has characterized the gestational diabetes market recently, with projections indicating a rise from its 8.37 billion dollar valuation in 2024 to 9.11 billion dollars in 2025, reflecting a compound annual growth rate (CAGR) of 8.9%. This historical growth trajectory stems from several key factors, including a heightened susceptibility to diabetes, advancements leading to more precise blood glucose monitoring, an expanding presence of insurance providers, a larger overall count of individuals diagnosed with diabetes, and the general increase in the diabetic patient demographic.

Gestational Diabetes Market Size Forecast: What's the Projected Valuation by 2029?
Projection indicates a robust expansion for the gestational diabetes market in the coming years, anticipated to reach a valuation of $12.78 billion by 2029, driven by an 8.8% compound annual growth rate throughout the forecast duration, primarily fueled by escalating obesity rates, wider adoption of cloud-based project solutions, augmented utilization of associated devices and applications, the rising incidence of diabetes linked to adverse lifestyle choices, heightened public health awareness, and the increasing prevalence figures for diabetes; key developments shaping this period encompass advancements in digital diabetes management applications, the advent of closed-loop control systems, progress in diabetes management technology, utilization of enzymatic technology, and novel medical innovations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report

What Are the Drivers Transforming the Gestational Diabetes Market?
The escalating prevalence of obesity, defined as a Body Mass Index (BMI) of 30 or greater, signifying levels of body fat that introduce considerable health hazards, is anticipated to fuel the expansion of the gestational diabetes market moving ahead.This surge in the obese population stems from several interconnected factors such as more inactive daily routines, greater intake of nutrient-poor, high-energy processed foodstuffs, underlying genetic tendencies, and restricted availability of physical activity and nutritious dietary choices.Managing gestational diabetes becomes vitally important for this demographic given that their elevated susceptibility to insulin resistance and substantial prenatal weight gain risks adverse outcomes for both the maternal and infant health if not appropriately controlled.Illustratively, data from the World Health Organization, an international body headquartered in Switzerland, revealed in March 2024 that around one in every eight individuals worldwide experienced obesity in 2022; this figure accompanies a tally of 2.5 billion adults aged 18 and over categorized as overweight, a subset of which includes 890 million people classified as obese, translating to 43 percent of adults being overweight and 16 percent afflicted by obesity, alongside 37 million children under five years carrying excess weight and over 390 million children and adolescents between the ages of 5 and 19 years being overweight, of whom 160 million are living with obesity; consequently, this expanding population struggling with obesity acts as a catalyst for the growth trajectory of the gestational diabetes market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp

What Long-Term Trends Will Define the Future of the Gestational Diabetes Market?
Leading enterprises within the gestational diabetes sector are concentrating their efforts on pioneering sophisticated technological offerings, specifically diagnostic assemblies for gestational diabetes, thereby facilitating rapid, precise, and ease-of-use techniques for timely identification. This diagnostic assembly, designed for gestational diabetes, functions as a crucial medical instrument for quantifying blood sugar concentrations and establishing any irregularities in glucose processing among expectant mothers, which supports both the prompt recognition and subsequent handling of the ailment. Illustratively, in August of 2024, DirectSens GmbH, an Austrian firm specializing in biotechnology, introduced the XpressGT RUO kit, a diagnostic package engineered for the determination of gestational diabetes, alongside conditions like endometriosis, insulin resistance, and hepatic illness; this device achieves precise quantification of 2-hydroxybutyrate (2-HB) concentrations present in venous samples, a compound naturally synthesized by the liver during its routine operations. Surging concentrations of 2-HB have been correlated with heightened reductive stress, a condition implicated in a spectrum of metabolic and weight-related dysfunctions, such as insulin resistance, and notably, this entire kit requires only standard clinical analytical equipment and furnishes outcomes within eight minutes, presenting a speedy and high-performing diagnostic resolution.

Which Segments in the Gestational Diabetes Market Offer the Most Profit Potential?
The gestational diabetesmarket covered in this report is segmented -

1) By Types: Type A1; Type A2; Other Types
2) By Treatment: Monitoring; Drug Treatment; Non-pharmacological treatment
3) By Administration: Oral; Intravenous; Other Administrations
4) By End User: Hospitals; Clinics; Home Care Settings; Diagnostic Centers

Subsegments:
1) By Type A1: Diet-Controlled Gestational Diabetes; Exercise-Controlled Gestational Diabetes
2) By Type A2: Insulin-Controlled Gestational Diabetes; Oral Medication-Controlled Gestational Diabetes
3) By Other Types: Pre-Gestational Diabetes; Gestational Diabetes With Complications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp

Which Firms Dominate the Gestational Diabetes Market by Market Share and Revenue in 2025?
Major companies operating in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, dic*kinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc

Which Regions Offer the Highest Growth Potential in the Gestational Diabetes Market?
North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20818

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.